Myelodysplastic Syndromes: all 2,165 studies
Page 3 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- CD34+ Enriched Transplants to Treat Myelodysplastic SyndromeNot yet recruitingNCT05617625Not applicable
- First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult PatientsRecruitingNCT05601726Phase 1/2
- Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDSAvailableNCT05593185
- Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid MalignanciesRecruitingNCT05588154
- Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAMLRecruitingNCT05584761Phase 1/2
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2
- Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)RecruitingNCT05483010Phase 2
- Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)RecruitingNCT05444348Not applicable
- Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDSRecruitingNCT05434598Not applicable
- Lifestyle-modifying Interventions in Low-risk MDS PatientsNot yet recruitingNCT05433805Not applicable
- Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require TransfusionsRecruitingNCT05384691Phase 2
- A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic SyndromesNot yet recruitingNCT05371730Early Phase 1
- A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsRecruitingNCT05365035Phase 2
- Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDSRecruitingNCT05350748
- Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDSRecruitingNCT05342584Phase 1
- The Patient Cohort of the National Center for Precision Medicine in LeukemiaRecruitingNCT05326919
- Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaRecruitingNCT05320198Phase 1/2
- Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)RecruitingNCT05308264Phase 1/2
- Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerRecruitingNCT05297734Not applicable
- Venetoclax Basket Trial for High Risk Hematologic MalignanciesRecruitingNCT05292664Phase 1
- Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT SurvivorsRecruitingNCT05194397Phase 2
- Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLRecruitingNCT05184842Phase 2Results posted
- Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESARecruitingNCT05181735Phase 1/2
- Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy StudyRecruitingNCT05175469
- CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)RecruitingNCT05143996Phase 1
- A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeRecruitingNCT05140811Phase 1/2
- Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
- Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) SyndromeRecruitingNCT05027945Phase 2
- ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT05010122Phase 1/2
- Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell TransplantationRecruitingNCT05005299Phase 1
- Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic SyndromeRecruitingNCT04999943Phase 1
- Repurposed Drugs to Improve Haematological Responses in Myelodysplastic SyndromesRecruitingNCT04997811Phase 2
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)RecruitingNCT04988555Phase 1/2
- Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDSRecruitingNCT04986657Not applicable
- Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy SpecimensRecruitingNCT04968834
- Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic ImpairmentRecruitingNCT04953910Phase 1
- Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal ImpairmentRecruitingNCT04953897Phase 1
- Faecal Microbiota Transplantation After Allogeneic Stem Cell TransplantationRecruitingNCT04935684Phase 2
- Improving Cognitive Function in Older Adults Undergoing Stem Cell TransplantRecruitingNCT04898790Not applicable
- Methods of T Cell Depletion Trial (MoTD)RecruitingNCT04888741Phase 2
- Biocollection in MyeloDysplastic Syndrome (P-MDS)RecruitingNCT04869683Not applicable
- A Study of BGB-11417 in Participants With Myeloid MalignanciesRecruitingNCT04771130Phase 1/2
- Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCTRecruitingNCT04764513Phase 1/2
- Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell TransplantRecruitingNCT04742634Phase 1/2
- The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyRecruitingNCT04726241Phase 1/2
- Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingNCT04708054Phase 2/3
- IS-free Treg HaploHCTRecruitingNCT04678401Phase 1
- National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
- A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic SyndromeRecruitingNCT04608110Phase 1
- Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS PatientsRecruitingNCT04587856Not applicable
- Study to Evaluate the Safety and Tolerability of EP0042RecruitingNCT04581512Phase 1/2
- Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?Not yet recruitingNCT04517175
- CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04493164Phase 2
- Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid NeoplasmsRecruitingNCT04460950
- Follow-up Study of ICUS and CCUS PatientsEnrolling by invitationNCT04428489
- A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)RecruitingNCT04419649Phase 2
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingNCT04375631Phase 1
- A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDSRecruitingNCT04358393Phase 1/2
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingNCT04282187Phase 2
- A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.RecruitingNCT04275518Phase 1
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingNCT04256317Phase 2/3
- Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood SamplesRecruitingNCT04251078
- Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic SyndromeRecruitingNCT04245397Phase 1
- A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04243785Phase 1
- A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaRecruitingNCT04239157Phase 2
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingNCT04195633Phase 2
- 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid MalignanciesRecruitingNCT04187703Early Phase 1
- Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02RecruitingNCT04167696Phase 1
- Activity Levels in Bone Marrow Transplant PatientsRecruitingNCT04115241
- CHIP/CCUS Natural History ProtocolRecruitingNCT04102423
- A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)Enrolling by invitationNCT04093570Phase 2
- A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsRecruitingNCT04064060Phase 3
- A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell TransplantationRecruitingNCT04024761Phase 1
- Combining Active and Passive DNA HypomethylationRecruitingNCT03999723Phase 2
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)RecruitingNCT03970096Phase 2
- Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) TransplantRecruitingNCT03964506Early Phase 1
- A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)RecruitingNCT03886662Phase 1/2
- Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity ConditioningRecruitingNCT03852407Phase 2
- CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCTRecruitingNCT03810196Not applicable
- A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesRecruitingNCT03802695Phase 1
- Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationRecruitingNCT03683433Phase 2
- Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecruitingNCT03661307Phase 1/2
- Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyRecruitingNCT03630991Phase 1
- Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic SyndromesRecruitingNCT03621241
- Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersRecruitingNCT03579875Phase 2
- Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideRecruitingNCT03533816Phase 1
- Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesRecruitingNCT03471260Phase 1/2
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT03452774
- RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCTRecruitingNCT03412409Phase 2
- HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantRecruitingNCT03326921Phase 1
- Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDSRecruitingNCT03300492Phase 1/2
- CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDSRecruitingNCT03291444Phase 1
- Institut Paoli Calmettes Myelodysplastic Syndromes DatabaseRecruitingNCT03275480
- Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant OutcomeRecruitingNCT03173937Phase 1/2
- SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)RecruitingNCT03113643Phase 1
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
- Umbilical Cord Blood Transplantation From Unrelated DonorsRecruitingNCT03016806
- A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)Not yet recruitingNCT02944955Phase 2
- Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2